<table border="1" cellpadding="0" cellspacing="0" width="648" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr>
<td>Concomitant Drug </td>
<td>Effect on Concentration of Lamotrigine or Concomitant Drug</td>
<td>Clinical Comment</td>
</tr>
<tr>
<td>Estrogen-containing oral contraceptive preparation containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel  </td>
<td>↓ lamotrigine    <br/>↓ levonorgestrel </td>
<td>Decreased lamotrigine levels approximately 50%.   Decrease in levonorgestrel component by 19%. </td>
</tr>
<tr>
<td>Carbamazepine (CBZ) and CBZ epoxide </td>
<td>↓ lamotrigine   <br/>
<br/>? CBZ epoxide </td>
<td>Addition of carbamazepine decreases lamotrigine concentration approximately 40%.<br/> May increase CBZ epoxide levels </td>
</tr>
<tr>
<td>Phenobarbital/Primidone </td>
<td>↓ lamotrigine </td>
<td>Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr>
<td>Phenytoin (PHT) </td>
<td>↓ lamotrigine </td>
<td>Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr>
<td>Rifampin </td>
<td>↓ lamotrigine </td>
<td>Decreased lamotrigine AUC approximately 40%. </td>
</tr>
<tr>
<td>Valproate </td>
<td>↑ lamotrigine   <br/>
<br/>? valproate </td>
<td>Increased lamotrigine concentrations slightly more than 2-fold.  <br/>Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients. </td>
</tr>
</tbody>
</table>